Kazia Therapeutics Limited (ASX:KZA)


right-arrow Created with Sketch. 0.03 (2.17%)
MCAP $186.8M
Last trade 15.52pm 29/11/2021 20mins delayed

Latest Announcements

29/11/2021KZAKazia Therapeutics Limited
24/11/2021KZAKazia Therapeutics Limited
16/11/2021KZAKazia Therapeutics Limited
15/11/2021KZAKazia Therapeutics Limited
11/11/2021 Price SensitivePSKZAKazia Therapeutics Limited
10/11/2021KZAKazia Therapeutics Limited
10/11/2021 Price SensitivePSKZAKazia Therapeutics Limited
04/11/2021KZAKazia Therapeutics Limited

Company Overview

Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The Company entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The Company entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

KZA in the news

Kazia Therapeutics (KZA) kicks off its brain cancer study, with the first…
Kazia Therapeutics (KZA) enrols its first patient in the upcoming phase one…
Kazia Therapeutics (KZA) is granted patents for the manufacture of Paxalisib by…
Kazia Therapeutics (KZA) will collaborate with Cornell University to investigate Kazia’s new…

Search Previous Announcements